Home / Bavarian Nordic Surpasses Q2 Forecast & Completes Priority Review Voucher Deal

Bavarian Nordic Surpasses Q2 Forecast & Completes Priority Review Voucher Deal

By: Jasmin Espinas

Updated: August 25, 2025

Published: August 22, 2025

Advertising Disclosure

The content featured in this article may include sponsored placements or affiliate partnerships. These do not reflect the views or recommendations of Financial Daily Update.

We do not guarantee the accuracy or reliability of information presented by third-party contributors or advertisers. You are encouraged to verify all product claims and service terms directly with the provider.

Some of the links on this page may lead to financial partners. If you take action through those links—such as applying for a loan or signing up for a service—we may earn compensation.

That said, all editorial content is written independently and without bias, in line with our mission to provide transparent and informative financial reporting.

Bavarian Nordic, a Denmark-based biotechnology company known for its infectious disease vaccines, has continued to expand its influence in global public health markets.

The company has also gained momentum through key commercial and regulatory developments.

This article covers two developments from the company’s Q2 update: stronger-than-expected quarterly revenue and the finalized sale of its Priority Review Voucher (PRV).

Bavarian Nordic Beats Q2 Revenue Forecast Ahead of Takeover Bid

Bavarian Nordic reported second-quarter revenue of 1.65 billion Danish crowns, surpassing expectations.

Analysts polled by the company had projected 1.46 billion. The growth came from strong performance across its travel vaccine segment and stable sales to government clients, particularly in public health preparedness programs.

Furthermore, the timing of the earnings report is significant. A takeover bid, led by Nordic Capital and Permira, is set to proceed, valuing Bavarian Nordic at around 19 billion crowns.

The offer, priced at 233 crowns per share, has the backing of the company’s board. However, the deal is facing pushback from its largest shareholder, ATP, a Danish pension fund holding a 10% stake. ATP has said it does not intend to support the bid.

CEO Paul Chaplin addressed the situation in an interview, stating the company is not actively seeking additional buyers but remains open to interest.

Bavarian Nordic Closes Sale of Priority Review Voucher

Bavarian Nordic has finalized the sale of its Priority Review Voucher for $160 million in cash. The company confirmed the transaction on July 31, following its initial announcement in June. The buyer has not been disclosed.

The U.S. Food and Drug Administration (FDA) granted Bavarian Nordic the voucher in February, after approving the company’s chikungunya vaccine, VIMKUNYA. This vaccine is cleared for use in individuals aged 12 and older.

Additionally, it was the first licensed chikungunya vaccine in the United States, which qualified Bavarian Nordic for the incentive.

The sale also provides immediate non-dilutive funding and strengthens the company’s balance sheet. Priority Review Vouchers are transferable assets that shorten FDA review timelines for future drug applications.

In addition, recent transactions for similar vouchers have ranged between $95 million and $110 million, placing Bavarian’s deal at the higher end of the market.

Conclusion

Bavarian Nordic enters the second half of the year with stronger-than-forecast revenue, improved full-year guidance, and an expanded cash position following the Priority Review Voucher sale.

Its vaccine portfolio continues to perform across both commercial and government markets, while the takeover bid has introduced new variables for shareholders evaluating the company’s longer-term direction.

For more updates on Bavarian Nordic and other corporate finance updates, subscribe to Financial Daily Update today.